Poc Hba1C Testing

Poc Hba1C Testing

POC HbA1c testing, known as a diagnostic test that measures the average blood level of glucose (sugar) over the past two to three months. Because it gives an estimate of how well a person's blood glucose levels have been controlled over a long period of time, the test is frequently used to diagnose and monitor diabetes. The expansion of POC HbA1c Testing is largely fueled by the rising incidence of diabetes. According to the International Diabetes Federation in 2021, around 537 million adults (20-79 years) are living with diabetes - 1 out of 10. By 2030, this number is expected to rise to 643 million, and by 2045, to 783 million. There is a growing demand for accurate and convenient diagnostic tests that can be performed outside of a healthcare facility as the number of people diagnosed with diabetes.

The Poc Hba1C Testing Market is expected to grow at a strong CAGR of 11% during the forecast period owing to the increasing technological advancements in POC testing devices. Moreover, the advancement of miniaturized, portable, and easy-to-use POC testing devices has expanded the availability and accessibility of HbA1c testing for diabetes. These gadgets give exact and solid outcomes in minutes, dispensing with the requirement for lab testing. For instance, in 2019, Abbott introduced the first-ever rapid Point-of-Care HbA1c Test to help in the diagnosis of diabetes.

• Based on product, the market is segmented into instruments and consumables. Amongst these, the instrument segment held a significant share of the market in 2021. It is anticipated that the development of portable and handheld instruments will make POC HbA1c Testing more accessible, making it possible to conduct the test in a variety of settings. Accordingly, the improvement of cutting-edge instruments for POC HbA1c Testing is supposed to drive the development of the market during the forecast period.
• By technology, the market is segmented into wireless ion–exchange HPLC, enzymatic assay, affinity binding chromatography, and turbidimetric inhibition immunoassay. Among these, the enzymatic assay is expected to grow with a significant CAGR during the forecast period. This is widely used to measure glucose-6-phosphate in a sample of blood or plasma that offer several advantages, including high specificity, sensitivity, and speed of analysis that evaluate a patient's glycemic control, which is crucial for effective diabetes management.
• On the basis of end-users, the market is segmented into hospitals, clinics, ambulatory surgery centers, and others. The hospitals held a major share of the Poc Hba1C Testing market in 2021. As per our analysis, hospitals held a significant share of the market in 2021. This is mainly due to the rising demand for urgent care and the presence of convenience and efficiency that can enhance the management of diabetes populations. These facilities contribute to the wider adoption and utilization of Poc Hba1C Testing.
• For a better understanding of the market adoption of the Poc Hba1C Testing industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Rest of World. North America dominated the Poc Hba1C Testing market in 2021. The rising incidence of diabetes and the growing demand for point-of-care (POC) testing are the significant drivers of the development of POC HbA1c testing in the North America region. In North America, diabetes has reached epidemic proportions, affecting a large number of people. Due to the rising prevalence, there is a significant demand for diagnostic tools for diabetes management and monitoring. Moreover, the key players have rapidly adopted strategic alliances such as collaboration, and joint ventures, to maintain a competitive edge in the global market. For instance, in August 2022, Precision Diabetes, Inc. and DxGen Corp. announced a strategic partnership in the U.S. to launch Epithod AutoDx, a fully automatic point-of-care (POC) analyzer that measures a comprehensive profile of diabetes tests.
• Some of the major players operating in the market include F. Hoffmann-La Roche Ltd, BD, QIAGEN, Danaher, Quidel Corporation, Siemens Healthcare GmbH, Abbott, BIOMÉRIEUX, Nova Biomedical, NIPRO.